KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Acquires 4,137 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 4,137 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was bought at an average price of $9.14 per share, with a total value of $37,812.18. Following the completion of the acquisition, the insider now owns 5,090,582 shares in the company, valued at approximately $46,527,919.48. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 7th, Venrock Healthcare Capital Par purchased 73,649 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average cost of $9.29 per share, for a total transaction of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average cost of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average cost of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:KALV opened at $9.33 on Thursday. The firm has a market capitalization of $461.09 million, a PE ratio of -2.56 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $16.88. The business’s 50 day moving average is $8.74 and its 200-day moving average is $10.58.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. On average, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on KALV. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Bank of America started coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $23.80.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC boosted its holdings in KalVista Pharmaceuticals by 0.5% during the third quarter. Suvretta Capital Management LLC now owns 4,212,005 shares of the specialty pharmaceutical company’s stock valued at $48,775,000 after purchasing an additional 20,000 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after buying an additional 1,700,000 shares during the period. Vanguard Group Inc. grew its position in KalVista Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock valued at $19,102,000 after acquiring an additional 104,716 shares during the period. State Street Corp raised its stake in KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after acquiring an additional 515,179 shares in the last quarter. Finally, Emerald Advisers LLC raised its stake in KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after acquiring an additional 192,091 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).